Subscribe to Search results

Christopher Pond stated that: "DH [Department of Health] did not seek to influence the decisions...with respect to the policy for allocating grants, how the CF should discharge its responsibilities to the beneficiaries, the kinds of applications the CF [Caxton Foundation] should grant or the quantum of the grants/payments it should make."

Published on:

The smaller number of Eileen Trust registrants enabled the Eileen Trust trustees to develop a much closer knowledge of each individual registrant's circumstances and give a more personal service to its beneficiaries.

Published on:

The trustees of the Eileen Trust arranged that the Department of Health should contact potential beneficiaries who had not yet registered.

Published on:

The Eileen Trust trustees questioned whether registrants were sufficiently aware of the benefits they could approach the Eileen Trust for and agreed in January 1999 to create a handbook to circulate to registrants about this.

Published on:

Following the provision of increased funding in response to Lord Archer's report, the Eileen Trust Board decided to adopt a minimum level of income which registrants should have in order to apply to the Trust for funding, determined by taking into account whether they were single, lived with a partner and had children.

Published on:

Minutes of a Eileen Trust Board meeting noted that the Board did not consider that support from the Trust should necessarily be secondary to that from state benefits.

Published on:

A scheme of payments for those "infected with HIV through blood or tissue transfer" in England, Wales and Northern Ireland was set up on 24 April 1992. It provided for the payment of fixed sums to people infected and "infected intimates" in different categories, depending on whether they were adult or younger, were married, and whether they had dependent children.

Published on:

Peter Stevens stated in his oral evidence that the Eileen Trust always suggested to registrants to try other fund options so that the Eileen Trust was a fallback.

Published on:

Although the Eileen Trust was administered by the same people as administered the MacFarlane Trust, the Eileen Trust's Board made the decisions which it thought best for the Eileen Trust and did not strictly follow the MacFarlane Trust's policies.

Published on:

Regular contact with office staff and case workers allowed registrants of the Eileen Trust to know what they could apply for and although there were subsequent handbooks that were budgeted to be produced from 2002 - 2011, from around 2001/02 the Board decided that newsletters and speaking to caseworkers were the best way to keep in contact with registrants.

Published on:

Following an "Away Day" with MacFarlane Trust trustees, Peter Stevens reported the feedback from this to the Eileen Trust Board that financial need must be a prerequisite for any disbursement by a charity.

Published on:

An article titled "Percutaneous Liver Biopsy and Chronic Liver Disease in Haemophiliacs" was published in The Lancet. It asserted that the high incidence of chronic liver disease was related to concentrate replacement therapy.

Published on:

In a letter from Dr Walford, it was emphasised that 90% of all post-transfusion hepatitis in the USA and elsewhere was caused by non-A, non-B hepatitis viruses. It was described as rapidly fatal.

Published on:

An article titled "Non-A, Non-B Hepatitis Associated With Chronic Liver Disease in a Haemodialysis Unit" in The Lancet described NANB hepatitis as relating to "high frequency of persistent hepatic dysfunction".

Published on:

In an article titled "Transfusion-associated hepatitis not due to viral hepatitis type A or B" it was recognised NANB hepatitis was the cause of many cases of post-transfusion hepatitis in comparison to other types.

Published on:

An article in the The Lancet titled "Non-A Non-B Hepatitis Post Transfusion Hepatitis", contained data that pointed to NANBH being the cause of a substantial cases of post-transfusion hepatitis.

Published on:

An article in The Yale Journal of Biology and Medicine titled, "Non-A, Non-B Hepatitis", outlined the role of NANB of subsequent development of chronic liver disease.

Published on:

An article in Gastroenterology titled, "Development of Chronic Liver Disease after Acute Non-A, Non-B Post-Transfusion Hepatitis: Role of _-globulin prophylaxis in its prevention", outlined the role of NANB of subsequent development of chronic liver disease.

Published on:

Article in Gastroenterology titled, "Post-transfusion hepatitis: The role of hepatitis B antibody", outlined the role of NANB of subsequent development of chronic liver disease.

Published on:

An article titled, "Non-A/Non-B Hepatitis: A Review and Interim Report of an Ongoing Prospective Study", outlined the role of NANB of subsequent development of chronic liver disease.

Published on: